Vincerx Pharma Inc.

NASDAQ: VINC · Real-Time Price · USD
0.05
-0.00 (-1.96%)
At close: Jun 09, 2025, 12:40 PM

Vincerx Pharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 1.31M 1.31M 1.31M 1.31M n/a n/a n/a n/a n/a n/a n/a 127K -1.27M -1.27M -1.27M
Cost of Revenue
270K 534K 792K 1.05M 1.02M 915K 898K 880K 863K 939K 1.04M 853K 595K 365K 22K -26K n/a
Gross Profit
-270K -534K 522K 268K 289K 399K -898K -880K -863K -939K -1.04M -853K -595K -238K -1.29M -1.25M -1.27M
Operating Income
-27.32M -31.46M -28.17M -30.69M -34.99M -42.61M -52.5M -59.08M -67.05M -73.57M -75.86M -76.89M -74.66M -62.66M -55.32M -37.7M -20.34M
Interest Income
373K 472K 608K 714K 884K 1.25M 1.51M 1.46M 1.13M 664K 204K n/a n/a n/a n/a n/a n/a
Pretax Income
-22.64M -30.07M -27.03M -28.9M -38.24M -40.16M -48.85M -56.01M -63.28M -65.37M -58.2M -65.84M -49.45M -39.31M -43.21M -19M -16.99M
Net Income
-22.64M -30.07M -27.03M -28.9M -38.24M -39.4M -39.91M -47.05M -53.12M -50.76M -51.77M -59.44M -44.25M -39.31M -43.21M -19M -16.99M
Selling & General & Admin
15.37M 15.98M 12.24M 11.87M 12.05M 13.64M 15.87M 16.87M 17.81M 18.95M 20.27M 21.47M 23.44M 22.57M 20.46M 15.05M 8.38M
Research & Development
11.68M 14.95M 15.14M 18.03M 22.42M 28.71M 36.63M 40.9M 46.77M 52.15M 53.12M 54.26M 51.22M 40.08M 34.86M 22.65M 11.95M
Other Expenses
n/a 154K 598K 828K 1.13M 1.25M 2.15M 1.82M 2.68M 2.4M 1.03M 1.14M -16K -8K 15K n/a n/a
Operating Expenses
27.32M 31.2M 27.65M 30.17M 34.47M 42.35M 52.5M 57.77M 64.58M 71.11M 73.39M 75.73M 74.66M 62.66M 55.32M 37.7M 20.34M
Interest Expense
n/a n/a 758K 758K 758K 758K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
23.98M 31.46M 28.17M 30.69M 34.99M 42.61M 52.5M 57.77M 64.58M 71.11M 73.39M 75.73M 74.66M 62.66M 55.32M 37.7M 20.34M
Income Tax Expense
-220.72K n/a 1.81M 1.44M 978.72K n/a -9.77M -9.42M -10.17M -14.61M -18.03M -11.4M -25.53M -23.65M -17.42M -24.33M -9.03M
Shares Outstanding (Basic)
3.58M 1.9M 11.65M 11.65M 21.4M 21.41M 21.34M 21.27M 21.19M 21.14M 21.08M 21M 20.9M 20.84M 17.69M 16.35M 13.73M
Shares Outstanding (Diluted)
3.58M 1.9M 11.65M 11.65M 21.4M 21.41M 21.34M 21.27M 21.19M 21.14M 21.08M 21M 20.9M 20.84M 17.69M 16.35M 13.73M
EPS (Basic)
-6.44 -5.62 -1.64 -1.43 -1.79 -1.85 -1.88 -2.22 -2.52 -2.42 -2.47 -3.06 -2.36 -2.28 -3.95 -2.62 -2.51
EPS (Diluted)
-6.44 -5.62 -1.64 -1.43 -1.79 -1.85 -1.88 -2.22 -2.52 -2.42 -2.47 -3.06 -2.36 -2.28 -3.95 -2.62 -2.51
EBITDA
-26.49M -30.37M -27.1M -29.65M -34.21M -42.1M -50.22M -55.74M -62.27M -68.57M -72.53M -74.83M -74.04M -62.27M -55.27M -37.7M -20.34M
EBIT
-23.98M -31.46M -28.17M -30.69M -35.39M -43.32M -53.21M -58.48M -64.89M -71.11M -73.39M -75.73M -74.66M -62.66M -60.46M -42.83M -25.47M
Depreciation & Amortization
826K 1.09M 1.07M 1.05M 1.02M 915K 898K 880K 863K 939K 1.04M 853K 595K 340K 5.37M 5.63M 5.68M